Agnete Fredriksen, Nykode | Being one of the top 50 women in bio in Europe | E07
Listen now
Description
We’re live from Oslo 🇳🇴 to catch up with Agnete Fredriksen, co-founder and CBO of Nykode (ex-Vaccibody). In this episode, we chat about being one of the leading women in bio in Europe, the Nordics, and immunotherapies. 💎 ABOUT THE SPEAKER Agnete founded the immunotherapy company Nykode in 2006 which is now worth around $500M. For her PhD she designed and developed the first Vaccibody vaccine molecules, improving the outlook for cancer patients. I’ve known Agnete for many years and I like her sharpness while having this Scandinavian humility. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/yk364wes 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter) https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. These might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:52] Welcome [00:01:36] Women in biotech [00:25:35] Gender equality on the board [00:42:10] Raising $45 million [00:47:47] How the science works [01:01:20] Explaining the clinical results [01:07:19] The immunotherapy field [01:17:02] Biotech in Oslo [01:21:08] Thanks for listening
More Episodes
We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and...
Published 10/28/24
Published 10/28/24